For more than eight years, India has remained in a regulatory limbo on one of the most basic aspects of modern healthcare delivery—the formal definition and regulation of over-the-counter (OTC) medicines. Despite repeated deliberations, expert committees, and draft proposals, the country still lacks a dedicated OTC drug policy. This prolonged indecision has significant implications for patient access, healthcare affordability, and pharmaceutical market growth.
The absence of a clearly defined OTC framework stands in stark contrast to global best practices, where OTC medicines play a critical role in promoting self-care, reducing healthcare burden, and improving access to treatment for common ailments.
A Timeline of Delays and Committees
The journey towards an OTC framework began in earnest in 2018, when the Union Health Ministry constituted a sub-committee comprising five State Drug Controllers. The committee was tasked with recommending a list of drugs that could be considered for OTC sale, along with conditions for their marketing and dispensing. After a detailed review of drugs currently governed under Schedules H, H1, G, X, and K of the Drugs Rules, 1945, the panel submitted its recommendations to the Ministry.
However, instead of implementing these findings, the Ministry constituted yet another three-member committee in 2019, chaired by then Haryana State Drugs Controller N.K. Ahooja. This committee took a more structured approach, recommending a two-tier classification of OTC medicines:
OTC drugs permitted for sale in general retail or grocery outlets, and
OTC drugs to be sold under the supervision of a registered pharmacist.
The Ahooja Committee emphasized the urgent need to formally define OTC medicines and establish specific regulatory provisions to govern their sale, promotion, and distribution. Importantly, it highlighted that a well-designed OTC framework could promote responsible self-care without compromising patient safety, while also reducing treatment costs for the general population.
In 2022, the Ministry released a draft amendment proposing changes to Schedule K of the Drugs Rules, 1945—raising expectations of imminent regulatory clarity. Yet, the final notification never followed. Instead, in early 2024, another committee was constituted to re-examine the issue in greater detail.
The Cost of Regulatory Inaction
The repeated formation of committees without decisive policy implementation has resulted in missed opportunities. In India, even medicines that are globally recognized as safe for OTC use remain classified under prescription-only schedules, such as H and H1, under the Drugs and Cosmetics Act, 1940 and Rules, 1945.
This regulatory rigidity disproportionately affects economically weaker sections of society. A large segment of the population continues to struggle with the cost of doctor consultations for minor ailments—expenses that could be avoided if a formal OTC policy were in place.
Common conditions such as acidity, indigestion, constipation, diarrhoea, cold, cough, allergies, and headaches can often be managed safely through pharmacist-guided self-medication. In the absence of a defined OTC schedule, however, patients are either forced into unnecessary doctor visits or resort to informal, unregulated medicine use—ironically increasing health risks.
Global Perspective: India Falling Behind
Globally, OTC drug categories are well established across developed markets such as the United States and the European Union. These frameworks balance patient safety with accessibility by:
- Clearly defining OTC drug lists
- Mandating appropriate labeling and consumer information
- Regulating advertising and promotion
- Strengthening the role of pharmacists as frontline healthcare advisors
- India’s lack of an OTC policy not only places it behind international peers but also undermines the potential of pharmacists as key healthcare providers in primary care settings.
- A Win-Win Opportunity for Patients and Industry
- A robust OTC regulatory framework would deliver multiple long-term benefits:
- For patients: Reduced healthcare costs, time savings, and easier access to treatment for minor ailments
- For pharmacists: Enhanced professional role in patient counseling and primary care
- For the pharmaceutical industry: Market expansion, innovation in consumer healthcare products, and regulatory certainty
- For the healthcare system: Reduced burden on doctors and public health infrastructure
- Clear guidelines on drug classification, labeling, advertising, and sale conditions would ensure patient safety while encouraging responsible self-care.
The Need for Decisive Action
India’s pharmaceutical market has waited long enough for regulatory clarity on OTC medicines. The evidence, expert recommendations, and international precedents are already in place. What is now required is policy resolve.
Rather than continuing the cycle of committee formation, the Union Health Ministry must demonstrate urgency and seriousness by finalizing and notifying a comprehensive OTC drug policy. Such a move would not only align India with global healthcare standards but also significantly improve access, affordability, and efficiency in the country’s healthcare ecosystem.
A well-defined OTC framework is no longer optional—it is an essential reform whose time has clearly come.
